Clinical performance of the SureX PCR HPV test versus hybrid capture assays (DH2/careHPV) in primary cervical cancer screening
The PCR-based SureX HPV test demonstrated good concordance with well-validated hybrid-capture HPV tests in detecting hrHPV and CIN2+/CIN3+. Despite its slightly suboptimal specificity, SureX HPV could be an alternative in primary screening due to its full genotyping capability.
Authors
- Remila Rezhake (ORCID: https://orcid.org/0000-0003-1842-6205)
- Wenyun Li (ORCID: https://orcid.org/0000-0002-0249-090X)
- Guzhanuer Abuduxikuer
- Guligeina Abudurexiti
- Qian Zhuo
- Gulixian Tuerxun
- Tangnuer Abulimiti
- Yi Ouyang (ORCID: https://orcid.org/0000-0002-8541-301X)
- Guzhalinuer Abulizi (ORCID: https://orcid.org/0000-0003-4337-3408)
- Kadeliya Muhetaer
- Shaliya Abuduwufu
Institutions
- Xinjiang Medical University (CN)
- Tumor Hospital of Xinjiang Medical University (CN)
Publication Details
- Journal
- Tumour Virus Research
- Published
- 2025-05-14
- DOI
- https://doi.org/10.1016/j.tvr.2025.200319
- Citations
- 2
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 2.71
Funders
- Natural Science Foundation of Xinjiang Province
- National Natural Science Foundation of China